Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Cash from Operations (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Cash from Operations data on record, last reported at 9446000.0 in Q3 2025.

  • For Q3 2025, Cash from Operations fell 20.09% year-over-year to 9446000.0; the TTM value through Sep 2025 reached 50073000.0, down 43.35%, while the annual FY2024 figure was 41397000.0, 20.99% up from the prior year.
  • Cash from Operations reached 9446000.0 in Q3 2025 per SNTI's latest filing, up from 13073000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 934675.0 in Q2 2021 and bottomed at 16304000.0 in Q1 2023.
  • Average Cash from Operations over 5 years is 9354497.11, with a median of 9752500.0 recorded in 2022.
  • Peak YoY movement for Cash from Operations: plummeted 868.08% in 2022, then skyrocketed 48.85% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 1142247.0 in 2021, then plummeted by 688.45% to 9006000.0 in 2022, then rose by 21.86% to 7037000.0 in 2023, then tumbled by 91.9% to 13504000.0 in 2024, then surged by 30.05% to 9446000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 9446000.0 in Q3 2025, 13073000.0 in Q2 2025, and 14050000.0 in Q1 2025.